by Vandana Singh for Benzinga

“BeiGene Ltd (NASDAQ: BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene’s blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics patent issued on June 13, 2023. Pharmacyclics is an AbbVie Inc (NYSE: ABBV) company.

As per a Bloomberg Law report, AbbVie filed a lawsuit against the China-based company alleging a patent violation related to Brukinsa…”

Continue reading the full article at its original source, linked here.